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Abstract 
Objectives 
To determine retention in HIV care for individuals not yet eligible for antiretroviral therapy (ART) 
and to explore factors associated with retention in a rural public health HIV programme.  
Methods 
HIV-infected adults (≥16 years) not yet eligible for ART, with CD4 cell count >200cells/μl January 
2007 - December 2007 were included in the analysis. Retention was defined by repeat CD4 count 
within 13 months. Factors associated with retention were assessed using logistic regression with 
clustering at clinic level.  
Results 
4,223 were included in the analysis (83.9% female). Overall retention was 44.9% with median time to 
return 201 days (interquartile range [IQR] 127-274). Retention by initial CD4 count 201-350, 351-
500, and >500 cells/μl was 51.6% (95% confidence interval [CI] 49.1-54.0), 43.2% (95% CI 40.5-
45.9), and 34.9% (95% CI 32.4-37.4) respectively. Compared to CD4 201-350 cells/μl, higher initial 
CD4 count was significantly associated with lower odds of retention (CD4 351-500 cells/μl adjusted 
odds ratio [aOR] 0.72, 95% CI 0.62-0.84; CD4 >500 cells/μl aOR 0.51, 95% CI 0.44-0.60). Male sex 
was independently associated with lower odds (aOR 0.80, 95% CI 0.67-0.96), and older age with 
higher odds of retention (for each additional year of age aOR 1.03, 95% CI 1.03-1.04).  
Conclusions 
Retention in HIV care prior to eligibility for ART is poor, particularly for younger individuals and 
those at an earlier stage of infection. Further work to optimise and evaluate care and monitoring 
strategies is required to realise the full benefits of the rapid expansion of HIV programmes in sub-
Saharan Africa. 
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Introduction 
South Africa is home to an estimated 5.7 million HIV infected people, approximately one in six of the 
global HIV infected population1. Since 2004, South Africa has seen the scale-up of the largest public 
sector antiretroviral therapy (ART) programme in the world, yet the number of new HIV infections 
per year is still considerably more than the number initiated on ART2. The scale-up of HIV 
counselling and testing services has led to increased population testing rates3-5. A considerable 
proportion of newly diagnosed individuals are not yet eligible for ART; in one study from Cape Town 
between 2001 and 2006 approximately 64% had CD4 cell count measurements above the threshold 
for eligibility at the time of diagnosis4. People living with HIV (PLHIV) who are not yet eligible for 
ART have received little attention as, in the early phase of antiretroviral roll-out, the priority for HIV 
services and funding agencies has been on identifying and treating individuals in need of ART6.  
Current WHO guidelines recommend clinical assessment and CD4 count monitoring every 6 months, 
to determine eligibility for ART as early as possible, and to prevent and treat HIV-related illnesses7. 
Establishing ART eligibility in a timely fashion for individuals enrolled in care is important to reduce 
the early mortality on ART consistently reported from programmes in sub-Saharan Africa (SSA)8-13. 
Retention in HIV care is also critical to facilitate integration of prevention strategies14-16. 
Despite the recognised importance of retention, there are precious few data from SSA on retention in 
pre-ART care. In particular, there have been no published studies which explore factors determining 
pre-ART retention, and hence it remains unclear which groups might benefit most from any targeted 
supportive intervention. Here we study factors associated with pre-ART retention in a large, 
decentralised HIV programme, linked to a population demographic platform in rural South Africa. 
 
Methods 
Hlabisa HIV Treatment and Care Programme 
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Hlabisa health sub-district is situated in northern KwaZulu-Natal, South Africa, covering an area of 
1430km2, with approximately 228,000 individuals living largely in scattered homesteads in rural 
areas. The Hlabisa HIV Treatment and Care Programme is a Department of Health initiative 
supported by the Africa Centre for Health and Population Studies (www.africacentre.com); details of 
the programme have been reported previously13,17. National ART guidelines are followed which 
during the study period denoted ART eligibility in the presence of a WHO stage IV condition or CD4 
cell count ≤200 cells/μl18.  
All clinics perform CD4 cell count testing and tests are routinely done on the same day for any 
individual newly diagnosed with HIV infection. CD4 cell counts are performed at the National Health 
Laboratory Service (NHLS) laboratory at Hlabisa Hospital, using the Beckman Coulter EPICS ® XL 
flow cytometer (Beckman Coulter, Inc.), and patients are requested to return to clinic for results two 
weeks from the date of sample collection. Decisions about ART eligibility are usually made on the 
basis of a single CD4 count result, rarely confirmed in a repeat sample.  
The model of care at the time of study for individuals not yet eligible for ART included individual 
counselling, with advice on healthy living, disclosure, partner notification and testing, transmission 
risk reduction measures, and family planning. All HIV-infected people regardless of disease stage 
were additionally invited to attend peer support groups at each clinic. Co-trimoxazole was indicated 
for individuals with CD4 count ≤200 cells/μl or WHO stage III/IV. Isoniazid preventive therapy (IPT) 
was not implemented at a programmatic level at the time of study. All individuals were advised to 
return for repeat clinical assessment, including clinical staging and CD4 count measurement, six 
months later. Whilst guidelines stipulated repeat CD4 cell count at twelve months if CD4 count >500 
cells/μl the actual practice varied and some clinics advised return after six months19.  
For routine programme monitoring and evaluation, all clinic and hospital attendances for CD4 
measurement from January 1st 2007 were recorded.  
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Africa Centre Demographic Information System 
A longitudinal demographic surveillance system has, since 2000, collected individual and household 
demographic data in the demographic surveillance area (DSA), within the Hlabisa health sub-district, 
which includes approximately 11,000 households and 85,000 individuals20. Data are collected 6-
monthly on residency status of household members, births, marriages, deaths, and migrations. Data 
regarding socio-economic status and employment are collected on an annual basis. Data are collated 
in the Africa Centre Demographic Information System (ACDIS). It is estimated that 30-40% of 
people in the HIV Treatment and Care Programme are resident in the surveillance area. 
Individual records within the HIV Treatment and Care Programme database and ACDIS were linked 
using the unique South African identity number in accordance with the Africa Centre data 
confidentiality protocols. Linkage was done to enable analysis of socio-demographic factors 
associated with retention and to determine vital status of individuals who did not return to care.  
 
Patients 
Patients were included in this analysis if they: had a first recorded CD4 cell count from a sample 
between Jan 1st 2007 – Dec 31st 2007; were ART naive; ≥16 years old at the time of CD4 test; and 
CD4 count result was >200 cells/μl. Patients were excluded if they: had missing identity number and 
age/date of birth; and if ART was initiated after the initial CD4 count but before any subsequent CD4 
count (it was assumed that these individuals initiated ART on the basis of clinical stage IV disease). 
 
Analysis 
Retention was defined as repeat CD4 count within 13 months (395 days) of the initial test; this 
allowed for visits up to one year from collection of initial test result (as this was the time 
recommended for those with CD4 count >500 cells/μl). Time to retention was measured using the first 
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repeat CD4 count within 13 months. CD4 counts within 14 days of the initial test (n = 101) were 
excluded from the analysis as it was highly likely that the patient had not received the result of the 
initial test before repeating the test. Further outcome measures were: change in CD4 cell count per 
month (measured between initial test and first subsequent test); and progression to ART eligibility 
(CD4 ≤200 cells/μl) within 13 months. End time for all follow-up was Jan 30th 2009.  
Additional analyses were performed with individuals linked to the demographic surveillance. 
Variables were chosen for the analysis either due to reported associations with retention in HIV 
treatment programmes or postulated effect on retention21,22. Residency status related to the defined 
living arrangements during the course of 13-month follow-up: non-residents were members of 
households, but not ordinarily resident, within the DSA; in-migrants were initially non-resident but 
became resident during follow-up; and out-migrants were initially resident but became non-resident. 
Socioeconomic data were taken from information collected between July and December 2007 (91.6%) 
or between January and June 2006 (8.4%), whichever was closer in time to the initial CD4 
measurement. Household economic status was determined using an asset wealth index23 and principal 
component analysis24; households were categorized into quintiles according to the wealth index.   
Descriptive statistics were used for the baseline characteristics and overall retention. Proportions 
analysis stratified by age group, sex, and initial CD4 cell count was used to enable full understanding 
of retention patterns. Logistic regression with clustering at clinic level was used to explore factors 
associated with retention in care. Multilevel logistic regression models were used to estimate the 
independence of measured variables (ρ) at clinic level. The effect of missing data was assessed by 
addition of a “missing” category for each variable in the model and calculation of the log-likelihood 
p-value. Median regression was used to determine factors associated with CD4 decline. STATA 
version 10.1 (StataCorp, College Station, Texas) was used for all analyses. 
 
Ethics statement 
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Ethical approval was obtained from the University of KwaZulu-Natal for the retrospective analysis of 
anonymised data from the HIV Treatment and Care Programme (BE066/07) and for the linkage of 
data from the HIV Treatment and Care Programme to the Africa Centre Demographic Information 
System (E134/06). Approval was also granted by the Research Office of the KwaZulu-Natal 
Department of Health. 
 
Results 
Patients 
10,140 individuals had CD4 cell count results recorded between Jan 1st and Dec 31st 2007. 4,223 
(41.6%) were eligible for inclusion in the primary analyses and, of those, 930 (22.0%) were matched 
to ACDIS and were included in the additional analyses (Fig. 1).  
3,543 (83.9%) were female. Median age was 31 years (interquartile range [IQR] 25-38) for females 
and 37 years (IQR 31-45) for males (P<0.001). Median CD4 count was 407 cells/μl (IQR 301-565) 
for females and 365 cells/μl (IQR 278-491) for males (P<0.001).The distribution across pre-defined 
CD4 strata was: 1,605 (38.0%) CD4 201-350 cells/μl; 1,278 (30.3%) CD4 351-500 cells/μl; 1,340 
(31.7%) CD4 >500 cells/μl.  
The individuals matched to ACDIS were similar to the unmatched individuals in terms of sex 
distribution and initial CD4 cell count, but were marginally older (Table 1). For the matched 
individuals, the majority remained resident within the demographic surveillance area (DSA) for the 13 
month period following the initial CD4 count. Most people (89.4% of those with data) lived within 
5km of the nearest primary health care clinic. 
 
Retention in care 
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Overall 1,896 patients (44.9%) returned for a subsequent CD4 count within 13 months. Of these, 
1,371 (72.3%) returned only once and 525 (27.7%) returned on more than one occasion. The 
proportion retained in care was highest amongst the group with lower initial CD4 cell count: 51.6% 
for CD4 cell count 201-350 cells/μl (95% confidence interval [CI] 49.1 - 54.0) versus 43.2% (95% CI 
40.5 - 45.9) for CD4 cell count 351-500 cells/μl and 34.9% (95% CI 32.4-37.4) for CD4 cell count 
>500 cells/μl. Retention stratified by age and initial CD4 cell count is illustrated in Fig. 2.  
The median time to return was 201 days (IQR 127-274). The time was shortest for the group with 
lower initial CD4 count: 175 days (IQR 109-251) for CD4 201-350 cells/μl versus 206 days (IQR 
153-279) for CD4 351-500 cells/μl and 230 days (IQR 162-310) for CD4 >500 cells/μl (P<0.001). 
 
Change in CD4 cell count and progression to ART eligibility 
The median decline in CD4 cell count between initial test and first subsequent test was 8.8 cells/μl per 
month (IQR -24.9 to +5.16), significantly greater with higher initial CD4 count:  -5.2 cells/μl per 
month for CD4 201-350 cells/μl; -10.5 cells/μl per month for CD4 351-500 cells/μl (P<0.01); and -
18.1 cells/μl per month for CD4 >500 cells/μl (P<0.01). In median regression, higher CD4 group and 
male sex were significantly associated with greater CD4 decline. There was no significant association 
with age. 
516 individuals (27.2% of all those who returned) progressed to CD4 ≤200 cells/μl within 13 months 
and, of those, 390 (75.6%) were recorded to have subsequently initiated antiretroviral therapy.  
 Factors associated with retention 
In multivariable analysis including all patients, higher initial CD4 count was associated with lower 
odds of retention (compared to CD4 201-350 cells/μl: adjusted odds ratio [aOR] 0.72 [95% CI 0.62-
0.84] for CD4 351-500 cells/μl; and aOR 0.51 [95% CI 0.44-0.60] for CD4 >500 cells/μl). Male sex 
was independently associated with lower odds of retention (aOR 0.80 [95% CI 0.67-0.96]). With 
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reference to age 16-25 years, older age was associated with increased likelihood of retention (aOR 
1.82 [95% CI 1.55-2.14] for 26-35 years; aOR 2.72 [95% CI 2.25-3.28] for 36-45 years; aOR 3.07 
[95% CI 2.43-3.89] for 46-55 years; and aOR 1.89 [95% CI 1.27-2.82] for >55 years). With age as a 
continuous variable, older age was also associated with increased retention (for each additional year 
of age aOR 1.03 [95% CI 1.03-1.04]). Positive matching to ACDIS was associated with higher odds 
of retention (aOR 1.57 [95% CI 1.32-1.87]). 
In further analysis with the 930 individuals matched to ACDIS, education level, household wealth, 
and distance from nearest clinic were not significantly associated with retention in univariable 
analysis. The results of multivariable analysis are displayed in Table 2. Male sex, higher initial CD4 
cell count, out-migration, full-time employment, and household size of greater than ten members were 
all associated with lower likelihood of retention in care. With reference to age 16-25 years, older age 
(26-35 years, 36-45 years, and 46-55 years) was associated with increased retention; with age as a 
continuous variable, older age was also significantly associated with retention (for each additional 
year of age, aOR 1.03 [95% CI 1.02-1.05]). In-migration was also associated with increased retention. 
In analyses stratified by sex, the associations with age, CD4 count, out-migration, employment, and 
household size remained significant for females. For males, the associations with CD4 count, 
employment and out-migration were similar, although only the relationship with out-migration 
retained statistical significance due to smaller numbers, and non-residency became significantly 
associated with lower retention (Table 3). 
 
Outcomes for people lost to follow-up 
432 of the 930 (46.5%) individuals matched to ACDIS did not return within 13 months for CD4 
testing (compared to 58.9% for the unmatched group, P<0.001). Of these, 21 (4.9%) were reported to 
have died within the 13 month period and 72 (16.7%) migrated out of the demographic surveillance 
area. The remaining 339 individuals (78.5%) were documented to be alive and still a member of the 
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demographic surveillance system at the end of the 13 month period following their initial CD4 cell 
count. 
 
Discussion 
Retention in long-term HIV care both before and after the initiation of ART is important not only to 
reduce individual HIV-related mortality and morbidity but also as a means to deliver ‘positive 
prevention’ interventions aimed at reducing ongoing transmission. It is of major concern, therefore, 
that in this large primary health care HIV programme under the existing model of care for individuals 
not yet eligible for ART, fewer than 50% returned within 13 months for repeat CD4 cell count.  
Retention in care after the initiation of ART has been the focus of much published work from sub-
Saharan Africa and is seen as a key indicator of programme performance25. Conversely, there has only 
been one small study focused specifically on retention in HIV care prior to eligibility for ART, which 
reported retention of only 31% at twelve months in an urban South African programme26. Pre-ART 
monitoring strategies using CD4 counts have been shown in mathematical models to maximise the 
benefit of HIV treatment programmes and to be cost-effective in a South African setting27,28. 
However, the rates of retention reported here are much less than assumed in these models and should 
prompt their re-evaluation. 
One plausible explanation for poor retention would be the lack of incentive for asymptomatic 
individuals to return for monitoring and previous work from our group has suggested that the majority 
return to care at the time of symptoms29. The package of care for individuals not yet eligible for ART 
has been limited in this setting, with co-trimoxazole only for those with late symptomatic disease and 
until now no routine implementation of isoniazid preventive therapy (IPT). This is likely to have 
limited the effectiveness of programmes as individuals will often return to care with opportunistic 
infections, possibly requiring hospitalisation, and ART will continue to be initiated late with 
consequent sustained high mortality rates30. Consistent with this we have reported no significant 
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change in the median CD4 count at ART initiation nor a reduction in the high early mortality rates in 
the first four years of the programme13.  
Recently updated national guidelines in South Africa recommend that individuals not yet eligible for 
ART are transferred to a ‘wellness programme’ for regular follow-up and repeat clinical assessment 
6-monthly31. This also incorporates the provision of isoniazid preventive therapy (IPT) to individuals 
without evidence of TB disease32. The evidence base to guide the framework of wellness programmes 
is poor and research is urgently required to determine optimal and cost-effective models of care.  
In this study, gender affected both access to care and retention in care. The proportion of males in this 
pre-ART population was even lower than that seen in antiretroviral treatment cohorts and likely 
reflects the different entry points to HIV care, with a large number of asymptomatic females enrolled 
in HIV care through antenatal HIV testing33. This might limit the generalisability of our findings to 
urban or work-based programmes with higher proportions of males. Male sex and full-time 
employment were associated with lower rates of retention and highlight the need to explore health 
care utilisation by men and to develop strategies to engage and retain men in HIV care, perhaps 
targeting work-based care34. Factors shown elsewhere to be important determinants of loss to follow-
up after ART initiation such as economic status and distance to treatment point were not shown to be 
significant in this context21,35-37. This is perhaps explained by the relatively low cost of 6-monthly 
visits to the clinic compared to monthly visits on ART. The relationship between larger household 
size and lower likelihood of retention may relate to care commitments which hinder clinic attendance 
or financial constraints from broader distribution of the household income38.  
The decline in CD4 count for those retained in care was considerably greater than that from natural 
history research studies in South Africa; although the fact it was greater in those with higher initial 
CD4 counts was consistent39,40. This large CD4 decline (equivalent to 105 cells/μl per year) may 
represent bias in that those with greater CD4 decline may have been more likely to return for follow-
up due to symptomatic progression. Additionally return visits may have been at the time of an 
intercurrent infection or other clinical episode which might itself lower the CD4 count. However, 
14 
 
these data support the hypothesis that retention in this setting is likely to be influenced more by 
symptomatic disease than by direct adherence to recommended monitoring strategies. 
The contribution of mortality and migration to the high rate of loss to follow-up was relatively minor 
and the majority of those lost to follow-up were alive and remained resident within the area. No 
detailed information regarding causes of death is available for the group lost to follow-up and thus no 
conclusions can be drawn whether this mortality was HIV-related and how much the high burden of 
TB locally may have contributed41. The relationship with migration is a complicated one. This rural 
area is characterised by high rates of circular migration related to urban employment and young adults 
who migrate to urban areas for employment often return to the family home when unwell42. This 
would explain why retention was better for those individuals who were categorised as non-resident at 
the time of first test but became resident and the opposite relationship that those who became non-
resident were less likely to have returned. 
Ongoing high HIV incidence in this area despite significant scale-up of ART highlights the urgent 
need for improved integration of HIV care and prevention43,44. Retention in long-term HIV care is 
important to enable the delivery of targeted biomedical and behavioural interventions aimed at 
reduction of onward transmission14,15. It is of concern, therefore, that retention was particularly poor 
for younger people with higher CD4 counts, those who may be responsible for a significant 
proportion of transmission45,46. Whilst there has been much recent interest in the concept of universal 
ART as prevention47, the evidence to support this will likely take several years to accumulate48, and it 
is imperative now that integrated care and prevention programmes are prioritised and adequately 
resourced.  
The main limitation of our study is that it is based on retrospective analysis of CD4 cell count data. 
There is emerging evidence that the loss to follow-up is considerable even between CD4 testing and 
collection of results49. We were unable to quantify this and our data should be interpreted as overall 
retention from the time of CD4 testing. Also we were unable to account for tests performed elsewhere 
and thus might have underestimate true retention. The proportion linked to the demographic 
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surveillance platform (22%) was relatively low. Of those who initially attended one of the six clinics 
situated within the demographic surveillance area, 46% were successfully linked. Whilst mobility of 
patients within the sub-district and drawing in of patients from outside the sub-district might partly 
explain this, it is also possible that incomplete patient identifiers hampered the linkage process. The 
linked group had better retention than the unlinked individuals, which might partly reflect the fact that 
the demographic surveillance area is less rural and more developed and there is greater access to 
services than the rest of the sub-district. 
In conclusion, we have demonstrated that under existing models of public sector HIV care retention 
prior to eligibility for ART is poor, particularly for younger individuals with higher initial CD4 cell 
count. The next phase of HIV counselling and testing scale-up is likely to significantly increase the 
number of diagnosed HIV-infected individuals in care but not yet in need of ART50. Trials to evaluate 
different models of pre-ART care or wellness programmes, both facility-based and community-based, 
are an urgent priority. If the substantial benefits of the massive scale-up of HIV treatment and care 
programmes are to be maintained then we need to build an evidence base with which to inform the 
design of programmes to offer comprehensive care throughout the continuum of HIV infection. 
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Table 1. Baseline characteristics of included individuals (n=4,223) 
Variable  
Matched 
individuals 
(n=930) 
Unmatched 
individuals 
(n=3,293) 
P-Value 
Sex, % male (95% CI)  16.6 (15.4-17.9) 14.2 (12.0-16.5) 0.075 
Age, yrs, median (IQR)  32 (26-41) 30 (24-38) <0.001 
CD4 count, cells/μl, 
median (IQR) 
 396 (297-546) 399 (297-556) 0.710 
Residency status Always resident 533 (57.3%)   
 
Always non-
resident 
245 (26.3%)   
 Partly in-migrant 41 (4.4%)   
 Partly out-migrant 111 (11.9%)   
Employment Unemployed 474 (51.0%)   
 Part-time 47 (5.1%)   
 Full-time 199 (21.4%)   
 Missing data 210 (22.6%)   
Education level None 81 (8.7%)   
 Primary 175 (18.8%)   
 Secondary 413 (44.4%)   
 Missing data 261 (28.1%)   
Household size 1-5 151 (16.2%)   
 6-10 286 (30.8%)   
 >10 236 (25.4%)   
 Missing data 257 (27.6%)   
CI, confidence interval; IQR, interquartile range
25 
 
Table 2. Logistic regression of factors associated with retention in care for matched individuals 
(n=930) 
Variable*  n uOR 95% CI aOR 95% CI P-Value 
Sex Female 797 1  1   
 Male 133 1.06 0.74-1.54 0.71 0.53-0.95 0.022 
Age, years 16-25 195 1  1   
 26-35 371 1.49 1.05-2.12 1.34 1.10-1.65 0.005 
 36-45 221 2.70 1.82-4.02 2.32 1.63-3.30 <0.001 
 46-55 121 3.62 2.23-5.87 2.82 1.88-4.21 <0.001 
 >55 22 1.84 0.76-4.46 1.91 0.64-5.71 0.246 
Initial CD4 
count, cells/μl 
201-350 347 1  1   
 351-500 308 0.65 0.47-0.89 0.71 0.55-0.90 0.005 
 >500 275 0.45 0.33-0.62 0.47 0.32-0.68 <0.001 
Residency 
status 
Resident 533 1  1   
 Non-resident 245 0.77 0.54-1.00 0.93 0.59-1.48 0.767 
 In-migrant 41 1.77 0.88-3.54 2.31 1.22-4.38 0.010 
 Out-migrant 111 0.38 0.25-0.58 0.40 0.22-0.72 0.002 
Employment Unemployed 474 1  1   
 Part-time 47 1.88 0.98-3.59 1.36 0.86-2.16 0.187 
 Full-time 199 0.77 0.55-1.08 0.68 0.47-0.98 0.036 
Household 
size 
1-5 151 1  1   
 6-10 286 0.98 0.66-1.46 0.98 0.67-1.44 0.921 
 >10 236 0.53 0.35-0.81 0.59 0.40-0.89 0.011 
 
uOR, unadjusted odds ratio; aOR, adjusted odds ratio; CI, confidence interval 
 
*Education, asset wealth index, and distance to nearest clinic were not significant in univariable 
analysis and were not included in the multivariable model. The effect of missing data was not 
significant for any variable (not shown) 
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Table 3. Multivariable analysis of factors associated with retention in care, by sex 
Variable  FEMALES (n=797) MALES (n=133) 
  aOR 95% CI P-Value aOR 95% CI P-Value 
Age, years 16-25 1   1   
 26-35 1.33 1.07-1.64 0.009 1.12 0.34-3.57 0.863 
 36-45 2.52 1.74-3.64 <0.001 1.33 0.38-4.71 0.655 
 46-55 3.10 1.79-5.36 <0.001 1.69 0.38-7.48 0.492 
 >55  2.16 0.50-9.31 0.303 0.89 0.08-9.82 0.926 
Initial CD4 count, 
cells/μl 
201-350 1   1   
 351-500 0.68 0.55-0.83 <0.001 0.90 0.49-1.65 0.733 
 >500 0.46 0.32-0.66 <0.001 0.55 0.26-1.15 0.112 
Residency status Resident 1   1   
 Non-resident 1.19 0.66-2.18 0.561 0.21 0.11-0.39 <0.001 
 In-migrant 2.01 0.85-4.76 0.111 2.12 0.59-7.65 0.250 
 Out-migrant 0.42 0.22-0.81 0.010 0.23 0.07-0.79 0.020 
Employment Unemployed 1   1   
 Part-time 1.66 0.84-3.30 0.147 0.66 0.23-1.91 0.447 
 Full-time 0.64 0.44-0.93 0.018 0.88 0.41-1.86 0.730 
Household size 1-5 1   1   
 6-10 0.99 0.71-1.38 0.939 1.03 0.33-3.23 0.948 
 >10 0.57 0.39-0.85 0.005 0.95 0.23-3.88 0.943 
aOR, adjusted odds ratio; CI, confidence interval 
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Figure 1. Inclusion of individuals in analyses  
 
 
*Africa Centre Demographic Information System 
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Figure 2. Retention stratified by age and initial CD4 cell count. A, Females. B, Males. 
A.
B.
 
